Company: NCNA
Filing Date: 2025-06-27
Form Type: 424B5
Source: 0001193125-25-151464
Chunk: 12

Company: NuCana plc
Filing Date: 2025-06-27
Form: 424B5
Chunk 12
---
 December 31, 2024, titled “Business,” “Risk Factors,” and “Operating and Financial Review and Prospects,” as well as other sections in this prospectus supplement and the documents or reports incorporated by reference in this prospectus supplement, including, for the avoidance of doubt, any “Supplemental Risk Factors” filed with our Form 6-Ksfrom time to time, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about:the development of NUC-3373 and NUC-7738, aswell as Acelarin, including statements regarding the expected initiation, timing, progress and availability of data from our clinical trials;

| • |     | the potential attributes and benefit of our ProTides and their competitive positions; |

| • |     | our ability to successfully commercialize our ProTides, if approved; |

| • |     | our financial performance; |

| • |     | our use of proceeds from any offering made pursuant to this prospectus; |

| • |     | our estimates regarding expenses, capital requirements and our need for additional financing; |

| • |     | our ability to acquire or in-license new product candidates; |

| • |     | our ability to maintain our listing on The Nasdaq Capital Market; |

| • |     | potential collaborations; and |

| • |     | the duration and strength of our patent portfolio. |

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this prospectus supplement or in the documents incorporated by reference in this prospectus supplement, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. For a summary of such factors, please refer to the section titled “Risk Factors” in this prospectus supplement, as updated and supplemented by the discussion of risks and uncertainties under “Risk Factors” contained in any supplements to this prospectus supplement and in our most recent Annual Report on Form 20-F,as revised or supplemented by our subsequent periodic reports filed under the Exchange Act, as well as any amendments thereto, including, for the avoidance of doubt, any “Supplemental Risk Factors” filed with our Form 6